Phase 1 MG Clinical Trials
10 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Phase 1
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Neuromyelitis Optica Spectrum Disorder (NMOSD)+6 more
Polina Stepensky120 enrolled1 locationNCT07085676
Recruiting
Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled6 locationsNCT04732065
Recruiting
Phase 1
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting
Phase 1Phase 2
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
MGMT-Unmethylated GlioblastomaHigh Grade GliomaMGMT-Methylated Glioblastoma
University of California, San Francisco70 enrolled5 locationsNCT06504381
Recruiting
Phase 1Phase 2
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
Newly Diagnosed MGMT Unmethylated Glioblastoma
Darell Bigner50 enrolled1 locationNCT05734560
Recruiting
Phase 1Phase 2
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Myasthenia GravisGeneralized MyastheniaAChR Myasthenia Gravis+1 more
COUR Pharmaceutical Development Company, Inc.54 enrolled17 locationsNCT06106672
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet against the innovator 5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone tablet conducted under fasting conditions in healthy volunteers.
5/2.5 mg s 4,5a-epoxy14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride/naloxone belongs to a class of medicines called opioid analgesics and is prescribed for the relief of severe pain.
Zenith Technology Corporation Limited26 enrolled1 locationACTRN12620000327987
Not Yet Recruiting
Phase 1
Comparative evaluation of the absorption and disposition in the body of a generic formulation of darifenacin 15 mg against the innovator product in healthy fed volunteers.
Bioequivalence assessment between two formulations of darifenacin 15 mg.
Center for Clinical Pharmacology Research Bdbeq S.A.24 enrolled1 locationACTRN12610000894099